T memory stem cells (T SCM ), a rare subset of memory lymphocytes endowed with enhanced capacity of self-renewal and the potential to reconstitute the full repertoire of memory and effector cells, have recently emerged as a central player in several physiological and pathological processes. T SCM cells have been shown to mediate superior anti-tumor responses (Gattinoni et al., 2009 , Gattinoni et al., 2011 , harbor leukemic cancer stem cells (Nagai et al., 2015) , and serve as a reservoir for HIV infection (Buzon et al., 2014) . Because of these wideranging clinical implications, it is of critical importance to improve our understanding of the molecular events that induce or maintain T SCM cells.
In this issue of EBiomedicine, Scholz et al. used pharmacological and genetic approaches to identify mTOR as a key signaling pathway regulating the formation of CD4 + and CD8 + T SCM cells (Scholz et al., 2016) .
It has previously been demonstrated in murine (Gattinoni et al., 2009) and human (Gattinoni et al., 2011) models that the formation of T SCM cells can be promoted by triggering WNT/β-catenin signaling. The finding that inhibition of the mTOR pathway can also favor the generation of T SCM cells has significant therapeutic implications as rapamycin and other mTOR inhibitors are FDA-approved agents that have already been used in T cell adoptive therapy clinical trials (clinicaltrials.gov.; NCT00074490, NCT01239368). As such, the contribution of Scholz et al. may accelerate the field in terms of bringing T SCM cells into the clinical arena. T SCM cells are an ideal cell population to employ in T cell-based immunotherapies because of their enhanced capacity to engraft and ability to persist for the long-term. Using a human-into-mouse xenogeneic transplantation model, the authors found that T SCM cells manufactured in rapamycin had increased persistence relative to control naïve or central-memory T cells, recapitulating prior observations obtained using naturally occurring T SCM cell populations (Gattinoni et al., 2011) . These findings are also consistent with a body of literature indicating that rapamycin-resistant human Th1/Tc1 cells have a remarkable ability to repopulate xenogeneic hosts and mediate graft-versus-host disease effects (Amarnath et al., 2010) . Additional in vivo functional endpoints, however, will be needed to determine the therapeutic potential of the rapamycin-generated T SCM cell populations as manufactured by Scholz et al. The authors argue that the WNT activator, TWS119, promoted T SCM cell generation not by the conventionally recognized mechanism (GSK3β inhibition and subsequent β-catenin stabilization) but rather via an off-target effect that involved mTOR inhibition; their conclusion was based in part on their observations that neither a physiological WNT3A ligand nor alternative GSK3β inhibitors supported T SCM formation in their hands. However, the authors used WNT3A at concentrations 100-fold lower than those used in previous studies that found an active role of WNT3A in the generation of both murine and human T SCM cells (Gattinoni et al., 2009 , Muralidharan et al., 2011 . In their experiments, the lack of activity of the GSK3β antagonist indirubin-3-monoxime was potentially attributable to its weak selectivity and inability to trigger downstream WNT signals (Meijer et al., 2003) . In sharp contrast, the highly selective, 6-bromoinduribin derivatives, which are capable of stabilizing β-catenin (Meijer et al., 2003) , have successfully been employed to generate T SCM cells (Gattinoni et al., 2009) . It is also important to underscore that the authors did not provide evidence of the ability of these 'ineffective' agents to activate WNT/β-catenin signaling. Indeed, Scholz et al. employed as a WNT operational readout the phosphorylation of GSK3β serine 9, a post-translational modification mediated by AKT and not involved in WNT signaling (McManus et al., 2005) (gold standard assays would consist of measurement of unphosphorylated β-catenin and WNT-reporter activity). In a final attempt to support their conclusion of TWS119 action outside of the GSK3β/WNT pathway realm, the authors used an elegant model involving β-and γ-catenin deficient T cells. However, conclusions based on these experiments carry the major caveat that WNT signal transmission is substantially maintained in double-deficient T cells (Jeannet EBioMedicine 4 (2016) , 2008) . Further research will therefore be required to more definitively test the extent to which GSK3β inhibitors such as TWS119 might mediate their effect on T SCM cells independent of the WNT pathway.
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In summary, Scholz et al. have tackled a critical issue in biomedicine relating to human CD4 + and CD8 + T memory stem cell generation and function. Although the molecular mechanism(s) of T SCM cell generation remain nebulous vis-à-vis the relative role of WNT/β-catenin or mTOR modulation, the current report certainly provides a nidus of information that will guide subsequent investigations. Hopefully, with the attainment of a refined molecular understanding and the development of alternative pharmacologic inhibitors, an ability to effectively modulate T SCM cells for therapeutic purposes will be realized.
